Fruquinitinib and capecitabine for maintenance in metastatic colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two oral drugs, fruquinitinib and capecitabine, as a first maintenance treatment after standard chemotherapy for metastatic colorectal cancer. It aims to see if this combination can help keep the cancer from growing for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced colorectal cancer that has spread to other parts of the body (metastatic).
- You have already completed standard first-line chemotherapy and your disease has not gotten worse (your tumors shrank or stayed the same).
- You have not taken the study drug fruquinitinib before.
- You are in good physical condition (able to do most day-to-day activities).
- Your major organs (like bone marrow, liver, and kidneys) are working well enough, based on recent blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
This trial tests a combination of two oral drugs (fruquintinib and camrelizumab) plus a chemotherapy infusion directly into the liver artery (HAIC) for people with advanced colorectal cancer that has spread to the liver. It's for those whose first treatment has stopped working and whose cancer is not the MSI-H type.
This trial is testing a combination of two oral anti-cancer drugs (fruquintinib and S-1) for people whose metastatic colorectal cancer has not responded to at least two standard treatments. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of three drugs (fruquintinib, camrelizumab, and capecitabine) for people with colorectal cancer that has spread or cannot be removed and has stopped responding to a standard first chemotherapy. It is for those whose cancer progressed after a specific first treatment called FOLFOXIRI.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.